Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1996-6-7
|
pubmed:abstractText |
The hemodynamic effects of long-term administration of octreotide in portal hypertension has not been established. In addition, whether long-term octreotide treatment prevents the development of portosystemic shunts has not yet been evaluated. Hence, the current study was undertaken to evaluate the effects of long-term administration of octreotide in rats with portal vein stenosis. Immediately after portal vein stenosis or sham operation, rats were given either a long-term octreotide administration of 100 micrograms/kg or a placebo every 12 hours by subcutaneous injection for 14 consecutive days. Systemic hemodynamics and regional blood flows, degree of mesenteric-systemic shunts, and plasma glucagon concentrations were measured after the final dose of octreotide or placebo. A fifth group of portal vein-stenosed rats received hemodynamic and plasma glucagon measurements after 1-day octreotide treatment given at 14 days after surgery. Long-term octreotide treatment modified the hyperdynamic circulation without affecting the degree of mesenteric-systemic shunts, and 1-day octreotide treatment decreased portal tributary blood flow without affecting the portal pressure, systemic hemodynamics, and degree of mesenteric-systemic shunts. Plasma glucagon levels were decreased in portal vein-stenosed rats receiving either long-term or 1-day octreodtide compared with rats receiving placebo. In contrast, chronic octreotide treatment did not affect any of the hemodynamic values or plasma glucagon levels in sham-operated rats. In conclusion, long-term administration of octreotide modified in part the development of portal hypertension and hyperdynamic circulation in portal vein-stenosed rats without affecting the degree of mesenteric-systemic shunts.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0270-9139
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
23
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
537-43
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8617434-Analysis of Variance,
pubmed-meshheading:8617434-Animals,
pubmed-meshheading:8617434-Constriction, Pathologic,
pubmed-meshheading:8617434-Drug Administration Schedule,
pubmed-meshheading:8617434-Gastrointestinal Agents,
pubmed-meshheading:8617434-Glucagon,
pubmed-meshheading:8617434-Hemodynamics,
pubmed-meshheading:8617434-Hypertension, Portal,
pubmed-meshheading:8617434-Male,
pubmed-meshheading:8617434-Octreotide,
pubmed-meshheading:8617434-Portal Pressure,
pubmed-meshheading:8617434-Portal Vein,
pubmed-meshheading:8617434-Rats,
pubmed-meshheading:8617434-Rats, Sprague-Dawley,
pubmed-meshheading:8617434-Regional Blood Flow,
pubmed-meshheading:8617434-Splanchnic Circulation
|
pubmed:year |
1996
|
pubmed:articleTitle |
Effects of long-term administration of octreotide in portal vein-stenosed rats.
|
pubmed:affiliation |
Department of Medicine, Veterans General Hospital, Taipei, Taiwan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|